8-K: Collegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase

Collegium Pharmaceutical executes an accelerated share repurchase agreement with Jefferies LLC to buy back $25 million of its common stock as part of a larger $150 million program.

Summary

• Collegium Pharmaceutical announced an accelerated share repurchase (ASR) agreement with Jefferies LLC on May 12, 2025.
• The ASR is for $25 million of the company's common stock.
• This is part of a $150 million share repurchase program authorized in January 2024.
• Collegium will pay $25 million to Jefferies LLC and receive an initial delivery of 692,281 shares.
• The initial delivery is based on the $28.89 closing stock price on May 9, 2025, and represents approximately 80% of the total shares expected to be repurchased under the ASR agreement.
• The final number of shares repurchased will be based on the volume-weighted average prices during the term of the ASR agreement.
• The final settlement is expected no later than the third quarter of 2025.
• As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding.

Sentiment

Score: 7

Explanation: The announcement of a share repurchase program is generally viewed positively as it can increase shareholder value and reflects management's confidence in the company's financial position. However, the document also includes standard forward-looking statements and risk disclosures, which temper the overall sentiment.

Positives

• The share repurchase program could signal management's confidence in the company's future prospects.
• The ASR agreement allows for a quicker repurchase of shares compared to open market purchases.
• Reducing the number of outstanding shares can increase earnings per share.

Risks

• The final number of shares repurchased depends on the volume-weighted average price of the stock, which could fluctuate.
• Developments or changes in the securities markets and fluctuations in the trading volume and market price of the Company's common stock could impact the program.
• The company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC contain other risks.

Future Outlook

The company expects to complete the final settlement of the ASR agreement no later than the third quarter of 2025, with the final number of shares repurchased depending on the volume-weighted average prices of Collegium's common stock during the term of the agreement.

Industry Context

Share repurchase programs are often used by companies with strong cash flow to return value to shareholders and can be seen as a sign of financial health. The pharmaceutical industry is no exception, with many companies using buybacks as part of their capital allocation strategy.

Comparison to Industry Standards

• Comparing Collegium's share repurchase program to other pharmaceutical companies, it's important to consider the size of the buyback relative to the company's market capitalization and cash reserves.
• For example, a company like Amgen, with a much larger market cap, might have a significantly larger buyback program in dollar terms, but the impact on share price could be proportionally smaller.
• Similarly, a smaller company like Collegium might see a more pronounced effect from a $25 million buyback.
• Other comparable companies could include those with similar market caps and product portfolios, such as Pacira BioSciences or BioDelivery Sciences International, to assess the relative scale of the repurchase program.

Stakeholder Impact

• Shareholders may benefit from the increased earnings per share and potential stock price appreciation.
• Employees may see the buyback as a sign of company stability and confidence in the future.
• Creditors may view the buyback as a sign of strong cash flow, but also a potential reduction in available cash for debt repayment.

Key Dates

Keywords

share repurchase, accelerated share repurchase, ASR, Collegium Pharmaceutical, Jefferies LLC, common stock, stock buyback